Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 6/20 | 0.47 |
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3221856 | 0.84 | CHRNB4 (0.46) | DRD4DRD2SLC6A4HTR1AHTR2A | |
| SCHEMBL3221853 | 0.84 | CHRNB4 (0.46) | DRD4DRD2SLC6A4HTR1AHTR2A | |
| SCHEMBL3221893 | 0.84 | CHRNB4 (0.46) | DRD4DRD2SLC6A4HTR1AHTR2A | |
| SCHEMBL3225728 | 0.82 | SLC6A4 (0.43) | DRD4SLC6A4 | |
| SCHEMBL7328652 | 0.82 | LTA4H (0.46) | DRD4DRD2SLC6A4HTR1AHTR2A | |
| SCHEMBL7328725 | 0.81 | DRD2 (0.46) | DRD4DRD2MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7322738 | 0.81 | LTA4H (0.45) | DRD2SLC6A4HTR1AHTR2A | |
| SCHEMBL7322367 | 0.80 | RAB9A (0.48) | — | |
| SCHEMBL7324506 | 0.80 | LTA4H (0.49) | — | |
| Hydrochloric Acid SCHEMBL7326201 | 0.80 | DRD2 (0.46) | DRD4DRD2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | ARGENTA DISCOVERY LIMITED (GB) | 2010-03-04 | — | — | US | disclosed |
| EP-2121688-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | Argenta Discovery Ltd (GB) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008099186-A1 | HETEROCYCLIC DERIVATIVES AS M3 MUSCARINIC RECEPTORS | ARGENTA DISCOVERY LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056565-A1 | Heterocyclic Derivatives as M3 Muscarinic Receptors | CHRM2, CHRM3, CHRM1 | DRD4 221/4885DRD2 87/4885MEN1 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.